Experimental corneal neovascularization using sucralfate and basic fibroblast growth factor

Australian and New Zealand Journal of Ophthalmology

Volumn 24, Issue 3, 1996, Pages 289-295

  Loughnan, Michael S ^a   Chatzistefanou, Klio ^a   Gonzalez, Evelyn M ^a   Flynn, Evelyn ^a   Adamis, Anthony P ^a   Shing, Yuen ^a   D'Amato, Robert J ^a   Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

angiogenesis; cornea; fibroblastic growth factor; neovascularisation; sucralfate

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; SUCRALFATE; FIBROBLAST GROWTH FACTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORNEA NEOVASCULARIZATION; NONHUMAN; RABBIT; SUSTAINED RELEASE PREPARATION; ACUTE DISEASE; ANIMAL; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CORNEA; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; FEMALE; PATHOLOGY; RADIATION EXPOSURE;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; CORNEA; CORNEAL NEOVASCULARIZATION; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; FIBROBLAST GROWTH FACTOR 2; RABBITS; SUCRALFATE;

EID: 0029658883     PISSN: 08149763     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-9071.1996.tb01596.x     Document Type: Article

References (26)

1. Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR. Control of angiogenesis with synthetic heparin substitutes. Science 1989;243:1490-3.
2. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992;313:355-64.
3. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. J Pediatr Surg 1993;28:445-50.
4. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991;174:1070-6.
5. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
6. Loughnan MS, Elder J, Kemp A. Treatment of a massive orbital-capillary hemangioma with interferon alfa-2b: short-term results. Arch Ophthalmol 1992;110:1366-7.
7. Loughnan MS, Heriot WJ, ODay J. Treatment of subfoveal choroidal neovascular membranes with systemic interferon-alpha 2a. Aust N Z J Ophthalmol. 1992;20:173-5.
8. Folkman J. Angiogenesis: initiation and modulation. Symp Fundam Cancer Res. 1983;36:201-8.
9. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9.
10. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993;100:9-14.
11. Klintworth GK. Corneal Angiogenesis: A comprehensive critical review. New York: Springer-Verlag; 1991:13-15.
12. Deutsch TA, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol. 1979;87:536-40.
13. Korey M, Peyman GA, Berkowitz R. The effect of hypertonic ointments on corneal alkali burns. Ann Ophthalmol. 1977;9:1383-7.
14. Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985;4;531-5.
15. Gimbrone MAJ, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974;52:413-27.
16. Fournier GA, Lutty GA, Watt S, Fenselau A, Patz A. A corneal micropocket assay for angiogenesis in the rat eye. Invest Ophthalmol Vis Sci, 1981;21:351-4.
17. Li WW, Grayson G, Folkman J, DAmore PA. Sustained-release endotoxin. A model for inducing corneal neovascularization. Invest Ophthalmol Vis Sci. 1991;32:2906-11.
18. Knighton DR, Phillips GD, Fiegel VD. Wound healing angiogenesis: indirect stimulation by basic fibroblast growth factor. J Trauma . 1990;30:134-44.
19. Gospodarowicz D, Bialecki H, Thakral TK. The angiogenic activity of the fibroblast and epidermal growth factor. Exp. Eye Res. 1991;28:501-14.
20. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors and synthetic chemoattractants. Am J Ophthalmol. 1978;86:445-61.
21. Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg . 1991;214:414-25.
22. Biglow C, Adler L, Appelbaum F. Allogenic bone marrow transplantation in irradiated adult rabbits. Transplantation 1987;44:351-4.
23. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev. 1987;8:95-114.
24. Terranova VP, Diflorio R, Lyall RM, Hic S, Freisel R, Maciag T. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol. 1985;101:2330-4.
25. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol. 1989; 108:671-82.
26. Montesano R, Vassali JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA. 1986;83:7297-301.